The interferon type i/iii response to respiratory syncytial virus infection in airway epithelial cells can be attenuated or amplified by antiviral treatment

Journal of Virology

Volumn 90, Issue 4, 2016, Pages 1705-1717

  McCutcheon, K M ^a   Jordan, R ^a   Mawhorter, M E ^b   Noton, S L ^b   Powers, J G ^c   Fearns, R ^b   Cihlar, T ^a   Perron, M ^a  

^a Discovery Virology   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; 2 [[6 [[[2 (3 HYDROXYPROPYL) 5 METHYLPHENYL]AMINO]METHYL] 2 [(3 MORPHOLINOPROPYL)AMINO] 1 BENZIMIDAZOLYL]METHYL] 6 METHYL 3 PYRIDINOL; ALPHA INTERFERON; BETA1 INTERFERON; BI D; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYBRID PROTEIN; INTERFERON; INTERFERON TYPE III; INTERLEUKIN 15; INTERLEUKIN 28A; INTERLEUKIN 29; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NUCLEOPROTEIN; PRESATOVIR; RANTES; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; YM 53403; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BOVINE RESPIRATORY SYNCYTIAL VIRUS; BOVINE RESPIRATORY SYNCYTIAL VIRUS INFECTION; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXICITY; DOWN REGULATION; EC50; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INNATE IMMUNITY; MALE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; METABOLISM; VIROLOGY;

ANTIVIRAL AGENTS; CELL LINE; EPITHELIAL CELLS; HUMANS; INTERFERONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84958093767     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02417-15     Document Type: Article

References (31)

1. Wu P, Hartert TV. 2011. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther 9:731-745. http://dx.doi.org/10.1586/eri.11.92.
2. Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. 2011. A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice. Can Respir J 18:e10-e19.
3. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. 1972. Broad-spectrum antiviral activity of virazole: 1-f8-Dribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706. http://dx.doi.org/10.1126/science.177.4050.705.
4. Empey KM, Peebles RS, Jr, Kolls JK. 2010. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 50:1258-1267. http://dx.doi.org/10.1086/651603.
5. Lay MK, González PA, León MA, Céspedes PF, Bueno SM, Riedel CA, Kalergis AM. 2013. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes Infect 15:230-242. http://dx.doi.org/10.1016/j.micinf.2012.11.012.
6. Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372:3-38.
7. Cowton VM, McGivern DR, Fearns R. 2006. Unraveling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol 87:1805-1821. http://dx.doi.org/10.1099/vir.0.81786-0.
8. Noton SL, Fearns R. 2015. Initiation and regulation of paramyxovirus transcription and replication. Virology 479-480:545-554. http://dx.doi.org/10.1016/j.virol.2015.01.014.
9. Ioannidis I, McNally B, Willette M, Peeples ME, Chaussabel D, Durbin JE, Ramilo O, Mejias A, Flaño E. 2012. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol 86:5422-5436. http://dx.doi.org/10.1128/JVI.06757-11.
10. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A. 2013. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog 9:e1003773. http://dx.doi.org/10.1371/journal.ppat.1003773.
11. Irving A, Williams BRG. 2009. Latest advances in innate antiviral defense. F1000 Biol Rep 1:22. http://dx.doi.org/10.3410/B1-22.
12. Gerlier D, Lyles DS. 2011. Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev 75:468-490. http://dx.doi.org/10.1128/MMBR.00007-11.
13. Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, Van Remoortere P, Janssens F, Wigerinck P, Andries K. 2008. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. Discovery of a morpholinopropylamino-benzimidazole derivative (TMC353121). J Med Chem 51:875-896.
14. Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, Carter MC, Chambers P, Chubb A, Cockerill GS, Collins PL, Dowdell VC, Keegan SJ, Kelsey RD, Lockyer MJ, Luongo C, Najarro P, Pickles RJ, Simmonds M, Taylor D, Tyms S, Wilson LJ, Powell KL. 2007. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 51:3346-3353. http://dx.doi.org/10.1128/AAC.00211-07.
15. Challa S, Scott AD, Yuzhakov O, Zhou Y, Tiong-Yip CL, Gao N, Thresher J, Yu Q. 2015. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother 59:1080-1087. http://dx.doi.org/10.1128/AAC.04119-14.
16. Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, Shimizu Y. 2005. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 65:125-131. http://dx.doi.org/10.1016/j.antiviral.2004.12.002.
17. Mason SW, Lawetz C, Gaudette Y, Do F, Scouten E, Lagace L, Simoneau B, Liuzzi M. 2004. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 32:4758-4767. http://dx.doi.org/10.1093/nar/gkh809.
18. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagacé L, Massariol MJ, Dô F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. 2005. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNAdependent RNA polymerase. J Virol 79:13105-13115. http://dx.doi.org/10.1128/JVI.79.20.13105-13115.2005.
19. Malykhina O, Yednak MA, Collins PL, Olivo PD, Peeples ME. 2011. A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression. J Virol 85:4792-4801. http://dx.doi.org/10.1128/JVI.02399-10.
20. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, Stephen McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin S, Chien JW. 2014. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371:711-722. http://dx.doi.org/10.1056/NEJMoa1401184.
21. Noton SL, Deflube LR, Tremaglio CZ, Fearns R. 2012. The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promotor. PLoS Pathog 8:e1002980. http://dx.doi.org/10.1371/journal.ppat.1002980.
22. Lever AR, Park H, Mulhern TJ, Jackson GR, Comolli JC, Borenstein JT, Hayden PJ, Prantil-Baun R. 2015. Comprehensive evaluation of poly(I:C) induced inflammatory response in an airway epithelial model. Physiol Rep 3:e12334. http://dx.doi.org/10.14814/phy2.12334.
23. Yoboua F, Martel A, Duval A, Mukawera E, Grandvaux N. 2010. Respiratory syncytial virus-mediated NF-kappa B p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKK beta. J Virol 84:7267-7277. http://dx.doi.org/10.1128/JVI.00142-10.
24. Daelemans D, Pauwels R, De Clercq E, Pannecouque C. 2011. A timeof-drug addition approach to target identification of antiviral compounds. Nat Protoc 6:925-933. http://dx.doi.org/10.1038/nprot.2011.330.
25. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 80:2396-2404. http://dx.doi.org/10.1128/JVI.80.5.2396-2404.2006.
26. Otsuki K, Maeda J, Yamamoto H, Tsubokura M. 1979. Studies on avian infectious bronchitis virus (IBV). III. Interferon induction by and sensitivity to interferon of IBV. Arch Virol 60:249-255.
27. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182:1305-1314. http://dx.doi.org/10.1164/rccm.201002-0221OC.
28. Stec DS, Hill MG, III, Collins PL. 1991. Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology 183:273-287. http://dx.doi.org/10.1016/0042-6822(91)90140-7.
29. Dochow M, Krumm SA, Crowe JE, Jr, Moore ML, Plemper RK. 2012. Independent structural domains in paramyxovirus polymerase protein. J Biol Chem 287:6878-6891. http://dx.doi.org/10.1074/jbc.M111.325258.
30. Noton SL, Nagendra K, Dunn EF, Mawhorter ME, Yu Q, Fearns R. 2015. Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter. J Virol 89:7786-7798. http://dx.doi.org/10.1128/JVI.00530-15.
31. Sun Y, Jain D, Koziol-White CJ, Genoyer E, Gilbert M, Tapia K, Panettieri RA, Jr, Hodinka RL, López CB. 2015. Immunostimulatory defective viral genomes from respiratory syncytial virus promote a strong innate antiviral response during infection in mice and humans. PLoS Pathog 11:e1005122. http://dx.doi.org/10.1371/journal.ppat.1005122.